Dr. Johnstone on Immediate Salvage Therapy for Prostate Cancer

Peter A. Johnstone, MD
Published: Friday, Sep 02, 2016


Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Oncologists are able to gain a deeper understanding of a patient's individual prostate cancer, including the disease stage, once the prostate is surgically removed, Johnstone explains. Additionally, pathological characteristics of the disease, such as extra capsularly extension, involvement of the seminal vesicles, and presence of positive margins and/or perineural invasion are known at this point.

Because of this, practitioners are able to better determine which patients should receive postoperative radiation therapy (RT). The challenge oncologists then face is how to integrate the postoperative RT for those patients and when it should be administered.

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Oncologists are able to gain a deeper understanding of a patient's individual prostate cancer, including the disease stage, once the prostate is surgically removed, Johnstone explains. Additionally, pathological characteristics of the disease, such as extra capsularly extension, involvement of the seminal vesicles, and presence of positive margins and/or perineural invasion are known at this point.

Because of this, practitioners are able to better determine which patients should receive postoperative radiation therapy (RT). The challenge oncologists then face is how to integrate the postoperative RT for those patients and when it should be administered.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x